Novartis Teams With Pear Therapeutics In Neurological Digital Health Pact

Duo aims to get Pear's THRIVE digital therapeutic approved, and to develop a new application to treat MS patients, then seek validation in clinical studies.

Digital screen
Duo Will Develop Clinically-Validated Software Used for Schizophrenia and MS • Source: Shutterstock

Signalling its intent to embrace emerging digital technologies in the realm of neuro-degenerative and psychiatric diseases, Novartis AG has joined Pear Therapeutics in a collaboration on prescription software applications aimed at treating patients with schizophrenia and multiple sclerosis.Prescription digital therapeutics are clinically validated, FDA-cleared software applications that show safety and efficacy in randomized clinical trials to improve patient outcomes.

"We see digital therapeutics as a potentially vital part of future treatment models across a range of diseases with high...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip